Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II CKVD regimen in early-line relapsed or refractory multiple myeloma
ChiCTR2500100365Phase 2Not yet recruiting
- Sponsor
- Beijing Chaoyang Hospital
- Start
- Apr 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aponermin, carfilzomib, venetoclax and dexamethasone in multiple myeloma (MM), sponsored by Beijing Chaoyang Hospital. Primary endpoint: Best complete response rate after CKVD treatment. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
aponermincarfilzomibvenetoclaxdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2500100365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100365.